Switzerland· 69428003
Omjjara 200 mg, Filmtabletten
A momelotinib product containing momelotinibum, registered in Switzerland by GlaxoSmithKline AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Momelotinib is registered in 15 of 19 countries.
Countries holding a registration under ATC L01EJ04 (momelotinib), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Momelotinib · ATC L01EJ04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of momelotinib costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $309.44 in Switzerland — a ×1929 gap.
- Switzerland: $309.44 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Momelotinib · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$309.44
- FR France$0.16
The record
At a glance
Swissmedic (Switzerland)- Active substance
- momelotinibum
- Manufacturer
- GlaxoSmithKline AG
- Country
- Switzerland (CH)
- ATC code
- L01EJ04
- ATC class
- Momelotinib
- Defined daily dose
- 0.2 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680694280037Ds 30 StkCHF 3849.4
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Momelotinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumOmjjara 200 mgGlaxoSmithKline Trading Services
- CzechiaOMJJARAGlaxoSmithKline Trading Services Limited, Dublin
- SpainOMJJARA 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULAGlaxosmithkline Trading Services Limited
- FinlandOmjjaraGlaxosmithkline Trading Services Limited
- FranceOMJJARA 200 mg, comprimé pelliculéGLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- IrelandOmjjara 200 mg film-coated tabletsGlaxoSmithKline Trading Services Limited
- IcelandOmjjaraGlaxoSmithKline Trading Services Limited
- NetherlandsOmjjara 200 mg, filmomhulde tablettenGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Omjjara
- Liechtenstein · Omjjara
- Norway · Omjjara
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/25a92821-3e49-4473-aec1-7ab61d24da3d GET /v1/drugs/25a92821-3e49-4473-aec1-7ab61d24da3d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "momelotinibum 200 mg",
"valid_from": "2025-03-01",
"limitations": "[{\"description\":\"Die Vergütung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nOMJJARA wird nur vergütet als Monotherapie zur Behandlung der primären Myelofibrose, der Myelofibrose nach Polycythaemia vera oder der Myelofibrose nach essentieller Thrombozythämie mit intermediärem oder hohem Risiko bei Erwachsenen mit moderater oder schwerer Anämie, die vorgängig mit Ruxolitinib behandelt wurden oder für eine Behandlung mit Ruxolitinib nicht in Frage kommen, und die nicht für eine allogene Stammzelltransplantation vorgesehen sind.<br>\\nNicht in Kombination mit Ruxolitinib.<br>\\nDie Verschreibung darf nur durch einen Facharzt für Hämatologie oder Onkologie erfolgen.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-03-01\",\"validTo\":\"2027-02-28\"}]",
"galenic_form": "Filmtabl 200 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2025-03-01",
"self_retention_pct": 10
}See everything about momelotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.